444 related articles for article (PubMed ID: 34857922)
1. The potential of mitochondrial genome engineering.
Silva-Pinheiro P; Minczuk M
Nat Rev Genet; 2022 Apr; 23(4):199-214. PubMed ID: 34857922
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic potential of engineering the mitochondrial genome.
Liu M; Ji W; Zhao X; Liu X; Hu JF; Cui J
Biochim Biophys Acta Mol Basis Dis; 2023 Oct; 1869(7):166804. PubMed ID: 37429560
[TBL] [Abstract][Full Text] [Related]
3. Development of mitochondrial gene-editing strategies and their potential applications in mitochondrial hereditary diseases: a review.
Gao Y; Guo L; Wang F; Wang Y; Li P; Zhang D
Cytotherapy; 2024 Jan; 26(1):11-24. PubMed ID: 37930294
[TBL] [Abstract][Full Text] [Related]
4. A bacterial cytidine deaminase toxin enables CRISPR-free mitochondrial base editing.
Mok BY; de Moraes MH; Zeng J; Bosch DE; Kotrys AV; Raguram A; Hsu F; Radey MC; Peterson SB; Mootha VK; Mougous JD; Liu DR
Nature; 2020 Jul; 583(7817):631-637. PubMed ID: 32641830
[TBL] [Abstract][Full Text] [Related]
5. Trends and prospects in mitochondrial genome editing.
Phan HTL; Lee H; Kim K
Exp Mol Med; 2023 May; 55(5):871-878. PubMed ID: 37121968
[TBL] [Abstract][Full Text] [Related]
6. In vivo mitochondrial base editing via adeno-associated viral delivery to mouse post-mitotic tissue.
Silva-Pinheiro P; Nash PA; Van Haute L; Mutti CD; Turner K; Minczuk M
Nat Commun; 2022 Feb; 13(1):750. PubMed ID: 35136065
[TBL] [Abstract][Full Text] [Related]
7. Gaining Insight into Mitochondrial Genetic Variation and Downstream Pathophysiology: What Can i(PSCs) Do?
Moreira JD; Gopal DM; Kotton DN; Fetterman JL
Genes (Basel); 2021 Oct; 12(11):. PubMed ID: 34828274
[TBL] [Abstract][Full Text] [Related]
8. CRISPR/Cas9-mediated base editors and their prospects for mitochondrial genome engineering.
Eghbalsaied S; Lawler C; Petersen B; Hajiyev RA; Bischoff SR; Frankenberg S
Gene Ther; 2024 May; 31(5-6):209-223. PubMed ID: 38177342
[TBL] [Abstract][Full Text] [Related]
9. Modeling mitochondrial DNA diseases: from base editing to pluripotent stem-cell-derived organoids.
Tolle I; Tiranti V; Prigione A
EMBO Rep; 2023 Apr; 24(4):e55678. PubMed ID: 36876467
[TBL] [Abstract][Full Text] [Related]
10. Current progress with mammalian models of mitochondrial DNA disease.
Stewart JB
J Inherit Metab Dis; 2021 Mar; 44(2):325-342. PubMed ID: 33099782
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Manipulation of mtDNA Heteroplasmy: A Shifting Perspective.
Jackson CB; Turnbull DM; Minczuk M; Gammage PA
Trends Mol Med; 2020 Jul; 26(7):698-709. PubMed ID: 32589937
[TBL] [Abstract][Full Text] [Related]
12. Tools for editing the mammalian mitochondrial genome.
Moraes CT
Hum Mol Genet; 2024 May; 33(R1):R92-R99. PubMed ID: 38779768
[TBL] [Abstract][Full Text] [Related]
13. Current strategies towards therapeutic manipulation of mtDNA heteroplasmy.
Pereira CV; Moraes CT
Front Biosci (Landmark Ed); 2017 Jan; 22(6):991-1010. PubMed ID: 27814659
[TBL] [Abstract][Full Text] [Related]
14. Concise Review: Heteroplasmic Mitochondrial DNA Mutations and Mitochondrial Diseases: Toward iPSC-Based Disease Modeling, Drug Discovery, and Regenerative Therapeutics.
Hatakeyama H; Goto Y
Stem Cells; 2016 Apr; 34(4):801-8. PubMed ID: 26850516
[TBL] [Abstract][Full Text] [Related]
15. Mitochondrial genome editing: strategies, challenges, and applications.
Lim K
BMB Rep; 2024 Jan; 57(1):19-29. PubMed ID: 38178652
[TBL] [Abstract][Full Text] [Related]
16. Advances in methods for reducing mitochondrial DNA disease by replacing or manipulating the mitochondrial genome.
Rai PK; Craven L; Hoogewijs K; Russell OM; Lightowlers RN
Essays Biochem; 2018 Jul; 62(3):455-465. PubMed ID: 29950320
[TBL] [Abstract][Full Text] [Related]
17. Genome editing in mitochondria corrects a pathogenic mtDNA mutation in vivo.
Gammage PA; Viscomi C; Simard ML; Costa ASH; Gaude E; Powell CA; Van Haute L; McCann BJ; Rebelo-Guiomar P; Cerutti R; Zhang L; Rebar EJ; Zeviani M; Frezza C; Stewart JB; Minczuk M
Nat Med; 2018 Nov; 24(11):1691-1695. PubMed ID: 30250142
[TBL] [Abstract][Full Text] [Related]
18. Specific elimination of mutant mitochondrial genomes in patient-derived cells by mitoTALENs.
Bacman SR; Williams SL; Pinto M; Peralta S; Moraes CT
Nat Med; 2013 Sep; 19(9):1111-3. PubMed ID: 23913125
[TBL] [Abstract][Full Text] [Related]
19. Mitochondria and Their Role in Human Reproduction.
Zou W; Slone J; Cao Y; Huang T
DNA Cell Biol; 2020 Aug; 39(8):1370-1378. PubMed ID: 31603716
[TBL] [Abstract][Full Text] [Related]
20. Mitochondrially targeted ZFNs for selective degradation of pathogenic mitochondrial genomes bearing large-scale deletions or point mutations.
Gammage PA; Rorbach J; Vincent AI; Rebar EJ; Minczuk M
EMBO Mol Med; 2014 Apr; 6(4):458-66. PubMed ID: 24567072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
